Agenus (AGEN) 10-Q 7 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 04, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Registrant Name	AGENUS INC
Entity Central Index Key	0001098972
Entity Current Reporting Status	Yes
Trading Symbol	AGEN
Security Exchange Name	NASDAQ
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common stock, par value $0.01
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		222,441,009
Entity File Number	000-29089
Entity Tax Identification Number	06-1562417
Entity Address, Address Line One	3 Forbes Road
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421
City Area Code	781
Local Phone Number	674-4400
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 119,366	$ 99,871
Accounts receivable	2,173	1,157
Prepaid expenses	10,678	10,746
Other current assets	3,446	2,009
Total current assets	135,663	113,783
Property, plant and equipment, net of accumulated amortization and depreciation of $48,354 and $47,201 at March 31, 2021 and December 31, 2020, respectively	27,149	26,790
Operating lease right-of-use assets	33,585	33,480
Goodwill	24,334	25,452
Acquired intangible assets, net of accumulated amortization of $12,176 and $11,841 at March 31, 2021 and December 31, 2020, respectively	9,994	10,886
Other long-term assets	4,190	4,123
Total assets	234,915	214,514
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
Current portion, long-term debt	1,463	833
Current portion, liability related to sale of future royalties and milestones	55,286	57,362
Current portion, deferred revenue	22,826	17,186
Current portion, operating lease liabilities	2,058	1,950
Accounts payable	19,477	17,015
Accrued liabilities	31,048	29,057
Other current liabilities	6,216	6,481
Total current liabilities	138,374	129,884
Long-term debt, net of current portion	18,913	18,879
Liability related to sale of future royalties and milestones, net of current portion	185,432	176,263
Deferred revenue, net of current portion	21,555	28,282
Operating lease liabilities, net of current portion	35,187	34,065
Contingent purchase price considerations	9,164	10,208
Other long-term liabilities	1,643	1,514
Commitments and contingencies
STOCKHOLDERS’ DEFICIT
Common stock, par value $0.01 per share; 400,000,000 shares authorized; 217,861,586 and 196,090,980 shares issued at March 31, 2021 and December 31, 2020, respectively	2,179	1,961
Additional paid-in capital	1,328,747	1,257,502
Accumulated other comprehensive income (loss)	(1,002)	2,772
Accumulated deficit	(1,519,584)	(1,465,907)
Total stockholders’ deficit attributable to Agenus Inc.	(189,660)	(203,672)
Non-controlling interest	(8,289)	(7,826)
Total stockholders’ deficit	(197,949)	(211,498)
Total liabilities, convertible preferred stock and stockholders’ deficit	234,915	214,514
Series C-1 Convertible Preferred Stock [Member]
CONVERTIBLE PREFERRED STOCK
Series C-1 convertible preferred stock; 10,459 and 12,459 shares designated, issued, and outstanding at March 31, 2021 and December 31, 2020, respectively	22,596	26,917
Series A-1 convertible preferred stock [Member]
STOCKHOLDERS’ DEFICIT
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at March 31, 2021 and December 31, 2020; liquidation value of $33,302 at March 31, 2021	0	0
Total stockholders’ deficit	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property plant and equipment, accumulated amortization and depreciation	$ 48,354	$ 47,201
Acquired intangible assets, accumulated amortization	$ 12,176	$ 11,841
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	217,861,586	196,090,980
Series C-1 Convertible Preferred Stock [Member]
Series C-1 convertible preferred stock, shares designated	10,459	12,459
Series C-1 convertible preferred stock, shares issued	10,459	12,459
Series C-1 convertible preferred stock, shares outstanding	10,459	12,459
Series A-1 convertible preferred stock [Member]
Series A-1 convertible preferred stock, shares designated	31,620	31,620
Series A-1 convertible preferred stock, shares issued	31,620	31,620
Series A-1 convertible preferred stock, shares outstanding	31,620	31,620
Series A-1 convertible preferred stock, liquidation value	$ 33,302

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total revenues	$ 11,719	$ 15,128
Operating expenses:
Cost of service revenue	(1,105)
Research and development	(36,677)	(36,363)
General and administrative	(16,352)	(10,613)
Contingent purchase price consideration fair value adjustment	1,044	4,384
Operating loss	(41,371)	(27,464)
Other income (expense):
Loss on modification of debt		(2,720)
Non-operating income (expense)	2,858	(1,052)
Interest expense, net	(15,890)	(14,035)
Net loss	(54,403)	(45,271)
Dividends on Series A-1 convertible preferred stock	(53)	(52)
Less: net loss attributable to non-controlling interest	(726)	(597)
Net loss attributable to Agenus Inc. common stockholders	$ (53,730)	$ (44,726)
Per common share data:
Basic and diluted net loss attributable to Agenus Inc. common stockholders	$ (0.27)	$ (0.31)
Weighted average number of Agenus Inc. common shares outstanding:
Basic and diluted	200,331	145,061
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$ (3,774)	$ 1,227
Other comprehensive income (loss)	(3,774)	1,227
Comprehensive loss	(57,504)	(43,499)
Research and Development [Member]
Revenue:
Total revenues	1,571	1,928
Service Revenue [Member]
Revenue:
Total revenues	1,629
Other Revenue [Member]
Revenue:
Total revenues	35	44
Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member]
Revenue:
Total revenues	$ 8,484	$ 13,156

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Non-controlling Interest [Member]	Accumulated Deficit [Member]	Series C-1 Convertible Preferred Stock [Member]	Series A-1 convertible preferred stock [Member]
Stockholders' Equity, Beginning Balance at Dec. 31, 2019	$ (231,337)	$ 1,378	$ 1,059,583	$ (1,324)	$ (5,981)	$ (1,284,993)		$ 0
Temporary Equity, shares at Dec. 31, 2019							12,000
Temporary Equity, Beginning Balance at Dec. 31, 2019							$ 26,917
Balance, shares at Dec. 31, 2019		137,819,000						32,000
Net loss	(45,271)				(597)	(44,674)
Other comprehensive income	1,227			1,227
Share-based compensation	2,397		2,397
Shares sold at the market	65,123	$ 247	64,876
Shares sold at the market, shares		24,716,000
Amendment of 2015 warrants and issuance of 2020 warrants	3,145		3,145
Payment of consultant in shares	12	$ 0	12
Payment of consultant in shares, shares		4,000
Exercise of stock options and employee share purchases	2,204	$ 8	2,196
Exercise of stock options and employee share purchases, shares		765,000
Stockholders' Equity, Ending Balance at Mar. 31, 2020	(202,500)	$ 1,633	1,132,209	(97)	(6,578)	(1,329,667)		$ 0
Temporary Equity, shares at Mar. 31, 2020							12,000
Temporary Equity, Ending Balance at Mar. 31, 2020							$ 26,917
Balance, shares at Mar. 31, 2020		163,304,000						32,000
Stockholders' Equity, Beginning Balance at Dec. 31, 2020	(211,498)	$ 1,961	1,257,502	2,772	(7,826)	(1,465,907)		$ 0
Temporary Equity, shares at Dec. 31, 2020							12,459
Temporary Equity, Beginning Balance at Dec. 31, 2020							$ 26,917
Balance, shares at Dec. 31, 2020		196,093,000						32,000
Net loss	(54,403)				(726)	(53,677)
Other comprehensive income	(3,774)			(3,774)
Share-based compensation	3,932		3,669		263
Shares sold at the market	60,859	$ 190	60,669
Shares sold at the market, shares		18,950,000
Payment of CEO payroll in shares	68		68
Payment of CEO payroll in shares, shares		19,000
Issuance of shares for services	20		20
Issuance of shares for services, shares		5,000
Conversion of series C-1 convertible preferred stock	4,321	$ 20	4,301				$ (4,321)
Conversion of Series C-1 convertible preferred stock, shares		2,000,000					(2,000)
Exercise of stock options and employee share purchases	2,526	$ 8	2,518
Exercise of stock options and employee share purchases, shares		796,000
Stockholders' Equity, Ending Balance at Mar. 31, 2021	$ (197,949)	$ 2,179	$ 1,328,747	$ (1,002)	$ (8,289)	$ (1,519,584)		$ 0
Temporary Equity, shares at Mar. 31, 2021							10,459
Temporary Equity, Ending Balance at Mar. 31, 2021							$ 22,596
Balance, shares at Mar. 31, 2021		217,863,000						32,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (54,403)	$ (45,271)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,729	1,700
Share-based compensation	4,001	2,397
Non-cash royalty revenue	(8,484)	(13,156)
Non-cash interest expense	15,611	13,844
Change in fair value of contingent obligations	(1,044)	(4,384)
Loss on modification of debt		(2,720)
Changes in operating assets and liabilities:
Accounts receivable	(1,039)	13,649
Prepaid expenses	53	465
Accounts payable	1,646	1,190
Deferred revenue	(1,087)	(1,875)
Accrued liabilities and other current liabilities	2,255	(8,471)
Other operating assets and liabilities	(1,982)	2,687
Net cash used in operating activities	(42,744)	(34,505)
Cash flows from investing activities:
Purchases of plant and equipment	(196)	(644)
Net cash used in investing activities	(196)	(644)
Cash flows from financing activities:
Net proceeds from sale of equity	60,859	65,123
Proceeds from employee stock purchases and option exercises	2,526	2,204
Repayments of debt	(232)	(500)
Payment of finance lease obligation	(191)	(1,214)
Net cash provided by financing activities	62,962	65,613
Effect of exchange rate changes on cash	(492)	12
Net increase in cash, cash equivalents and restricted cash	19,530	30,476
Cash, cash equivalents and restricted cash, beginning of period	102,505	61,808
Cash, cash equivalents and restricted cash, end of period	122,035	92,284
Supplemental cash flow information:
Cash paid for interest	278	204
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities	991	246
Issuance of common stock	20	12
Insurance financing agreement	987
Lease right-of-use assets obtained in exchange for new operating lease liabilities	1,116	7,467
Lease right-of-use assets obtained in exchange for new finance lease liabilities	156	$ 2,434
Series C-1 Convertible Preferred Stock [Member]
Supplemental disclosures - non-cash activities:
Conversion of series C-1 convertible preferred stock to common stock, $0.01 par value	$ 4,321

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Supplemental disclosures - non-cash activities:
Common stock, par value	$ 0.01	$ 0.01
Preferred stock, par value	$ 0.01	$ 0.01

Business, Liquidity and Basis o

Business, Liquidity and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Description Of Business [Abstract]
Business, Liquidity and Basis of Presentation	Note A - Business, Liquidity and Basis of Presentation Agenus Inc. (including its subsidiaries, collectively referred to as “Agenus,” the “Company,” “we,” “us,” and “our”) is a clinical-stage immuno-oncology (“I-O”) company advancing an extensive pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen vaccines, to fight cancer and infections. Our business is designed to drive success in I-O through speed, innovation and effective combination therapies. We believe that combination therapies and a deep understanding of each patient’s cancer will drive substantial expansion of the patient population benefiting from current I-O therapies. In addition to a diverse pipeline, we have assembled fully integrated end-to-end capabilities including novel target discovery, antibody generation, cell line development and current good manufacturing practice manufacturing. We believe that these fully integrated capabilities enable us to produce novel candidates on timelines that are shorter than the industry standard. Leveraging our science and capabilities, we have forged important partnerships to advance our innovation. We are developing a comprehensive I-O portfolio driven by the following platforms and programs, which we intend to utilize individually and in combination: • our multiple antibody discovery platforms, including our proprietary display technologies, designed to drive the discovery of future CPM antibody candidates; • our antibody candidate programs, including our CPM programs; • our vaccine programs, including Prophage™, AutoSynVax™ and PhosPhoSynVax ™; • our saponin-based vaccine adjuvants, principally our QS-21 Stimulon™ adjuvant, or QS-21 Stimulon; and • our cell therapy subsidiary, AgenTus Therapeutics, Inc., which is designed to drive the discovery of future adoptive cell therapy, or “living drugs” programs. Our business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of our collaborations. Our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of our strategy is to develop and commercialize some of our product candidates by continuing our existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations. Our cash and cash equivalents at March 31, 2021 were $119.4 million, an increase of $19.5 million from December 31, 2020. We have incurred losses since our inception. As of March 31, 2021, we had an accumulated deficit of $1.5 billion. During the past five years, we have successfully financed our operations through corporate partnerships, advance royalty sales and the sale of equity. Based on our current plans and projections, we believe that our cash resources of $119.4 million as of March 31, 2021, plus additional funding we anticipate from corporate events, will be sufficient to satisfy our liquidity requirements through the end of the year and into 2022. We are presently in financing, partnership, and out licensing discussions which, if consummated, could extend our cash resources further into and beyond 2022. Until we are successful in our efforts for capital infusion through these transactions or other financing options, and because the completion of such transactions is not entirely within our control, in accordance with accounting guidance we are required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Management continues to address the Company’s liquidity position and has the flexibility to adjust spending as needed in order to preserve liquidity. In March 2020, in response to the COVID-19 pandemic, we streamlined our organization, which included a headcount reduction, and our CEO, Dr. Garo Armen, elected to receive his base salary in stock rather than cash for the remainder of 2020 and through the first half of 2021. We continuously evaluate the likelihood of success of our programs. As such, our decisions to continue to fund or eliminate funding of each of our programs are predicated on these determinations, on an ongoing basis. We expect our potential sources of funding to include: (1) collaborations, out-licensing and/or partnering opportunities for our portfolio programs and product candidates with multiple parties (2) renegotiating third party agreements, (3) selling assets, (4) securing additional debt financing and/or (5) selling equity securities. T he accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of our management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of our financial position and operating results. All significant intercompany transactions and accounts have been eliminated in consolidation. Operating results for the three months ended March 31, 2021 , are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 . For further information, refer to our consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 16 , 2021 . The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. For our foreign subsidiaries, the local currency is the functional currency. Assets and liabilities of our foreign subsidiaries are translated into U.S. dollars using rates in effect at the balance sheet date while revenues and expenses are translated into U.S. dollars using average exchange rates during the period. The cumulative translation adjustment resulting from changes in exchange rates are included in the consolidated balance sheets as a component of accumulated other comprehensive loss in total stockholders’ deficit.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Note B - Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our Amended and Restated Directors’ Deferred Compensation Plan, or “DDCP”). Diluted loss per common share is calculated by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our DDCP) plus the dilutive effect of outstanding instruments such as warrants, stock options, non-vested shares and convertible preferred stock. Because we reported a net loss attributable to common stockholders for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. The following securities have been excluded from the computation of diluted weighted average shares outstanding as of March 31, 2021 and 2020, as they would be anti-dilutive (in thousands): Three Months Ended March 31, 2021 2020 Warrants 1,950 2,025 Stock options 29,960 27,707 Non-vested shares 1,142 888 Series A-1 convertible preferred stock 333 333 Series C-1 convertible preferred stock 10,459 12,459

Investments

Investments	3 Months Ended
	Mar. 31, 2021
Cash And Cash Equivalents [Abstract]
Investments	Note C - Investments Cash equivalents consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Cost Estimated Fair Value Cost Estimated Fair Value Institutional money market funds $ 94,928 $ 94,928 $ 64,256 $ 64,256 U.S. Treasury Bills 10,003 10,003 20,000 20,000 Total $ 104,931 $ 104,931 $ 84,256 $ 84,256 As a result of the short-term nature of our investments, there were minimal unrealized holding gains or losses for the three months ended March 31, 2021 and 2020.

Goodwill and Acquired Intangibl

Goodwill and Acquired Intangible Assets	3 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Acquired Intangible Assets	Note D - Goodwill and Acquired Intangible Assets The following table sets forth the changes in the carrying amount of goodwill for the three months ended March 31, 2021 (in thousands): Balance, December 31, 2020 $ 25,452 Foreign currency translation adjustment (1,118 ) Balance, March 31, 2021 $ 24,334 Acquired intangible assets consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): As of March 31, 2021 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 16,698 $ (10,438 ) $ 6,260 Trademarks 4-4.5 years 1,245 (945 ) 300 Other 2-7 years 2,232 (793 ) 1,439 In-process research and development Indefinite 1,995 — 1,995 Total $ 22,170 $ (12,176 ) $ 9,994 As of December 31, 2020 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 17,013 $ (10,112 ) $ 6,901 Trademarks 4-4.5 years 1,310 (980 ) 330 Other 2-6 years 2,272 (749 ) 1,523 In-process research and development Indefinite 2,132 — 2,132 Total $ 22,727 $ (11,841 ) $ 10,886 The weighted average amortization period of our finite-lived intangible assets is 9 years. Amortization expense related to acquired intangibles is estimated at $1.6 million for the remainder of 2021, $2.2 million for the year ending December 31, 2022, $1.7 million for the year ending December 31, 2023 and $0.6 million for the each of the years ending December 31, 2024 and 2025.

Debt

Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Debt	Note E - Debt Debt obligations consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): Debt instrument Balance at March 31, 2021 Current Portion: Debentures $ 146 Other 1,317 Long-term Portion: 2015 Subordinated Notes 12,716 Other 6,197 Total $ 20,376 Debt instrument Balance at December 31, 2020 Current Portion: Debentures $ 146 Other 687 Long-term Portion: 2015 Subordinated Notes 12,682 Other 6,197 Total $ 19,712 As of March 31, 2021 and December 31, 2020, the principal amount of our outstanding debt balance was $20.7 million and $20.0 million, respectively. Payroll Protection Program In May 2020, we entered into promissory notes with Bank of America, NA for aggregate loan proceeds of approximately $6.2 million (collectively, the “Loan”) under the Small Business Administration (the “SBA”) Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security Act of 2020 (the “CARES Act”). Though we have not yet finalized our forgiveness submission, we believe we used at two-year The Loan may be forgiven partially or fully if the Loan proceeds are used for covered payroll costs, rent and utilities, provided that such amounts are incurred during the twenty-four week period commencing on receipt of the Loan proceeds, and at least 60% of any forgiven amount has been used for covered payroll costs. Any forgiveness of the Loan will be subject to approval by the SBA and will require us to apply for such treatment in the future. As we have not yet finalized our forgiveness submission, we cannot yet determine if the Loan will be partially or fully forgiven. Therefore, we have classified the Loan proceeds as debt in our condensed consolidated balance sheet.

Liability Related to the Sale o

Liability Related to the Sale of Future Royalties and Milestones	3 Months Ended
	Mar. 31, 2021
Liability Related To Sale Of Future Royalties And Milestones [Abstract]
Liability Related to the Sale of Future Royalties and Milestones	Note F – Liability Related to the Sale of Future Royalties and Milestones The following table shows the activity within the liability account in the three months ended March 31, 2021 (in thousands): Period from December 31, 2020 to March 31, 2021 Liability related to sale of future royalties and milestones - beginning balance $ 234,041 Non-cash royalty revenue (8,484 ) Non-cash interest expense recognized 15,562 Liability related to sale of future royalties and milestones - ending balance 241,119 Less: unamortized transaction costs (401 ) Liability related to sale of future royalties and milestones, net $ 240,718 Healthcare Royalty Partners In January 2018, we, through our wholly-owned subsidiary Antigenics, LLC (“Antigenics”), entered into a Royalty Purchase Agreement (the “HCR Royalty Purchase Agreement”) with Healthcare Royalty Partners III, L.P. and certain of its affiliates (collectively, “HCR”). Pursuant to the terms of the HCR Royalty Purchase Agreement, we sold to HCR 100% of Antigenics’ worldwide rights to receive royalties from GlaxoSmithKline (“GSK”) on sales of GSK’s vaccines containing our QS-21 Stimulon adjuvant. At closing, we received gross proceeds of $190.0 million from HCR. Although we sold all of our rights to receive royalties on sales of GSK’s vaccines containing QS-21, as a result of our obligation to HCR, we are required to account for these royalties as revenue when earned, and we recorded the $190.0 million in proceeds from this transaction as a liability on our condensed consolidated balance sheet that will be amortized using the interest method over the estimated life of the HCR Royalty Purchase Agreement. The liability is classified between the current and non-current portion of liability related to sale of future royalties and milestones in the condensed consolidated balance sheets based on the estimated recognition of the royalty payments to be received by HCR in the next 12 months from the financial statement reporting date. During the three months ended March 31, 2021, we recognized $8.5 million of non-cash royalty revenue, and we recorded $15.6 million of related non-cash interest expense related to the HCR Royalty Purchase Agreement. As royalties are remitted to HCR from GSK, the balance of the recorded liability will be effectively repaid over the life of the HCR Royalty Purchase Agreement. To determine the amortization of the recorded liability, we are required to estimate the total amount of future royalty payments to be received by HCR. The sum of these amounts less the $190.0 million proceeds we received will be recorded as interest expense over the life of the HCR Royalty Purchase Agreement. Periodically, we assess the estimated royalty payments to be paid to HCR from GSK, and to the extent the amount or timing of the payments is materially different from our original estimates, we will prospectively adjust the amortization of the liability. During the three months ended March 31, 2021, our estimate of the effective annual interest rate over the life of the agreement increased to 28.3%, which results in a retrospective interest rate of 23.6%.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2021
Other Liabilities Disclosure [Abstract]
Accrued Liabilities	Note G - Accrued Liabilities Accrued liabilities consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Payroll $ 10,966 $ 7,643 Professional fees 5,205 4,457 Contract manufacturing costs 5,669 6,274 Research services 4,348 4,649 Other 4,860 6,034 Total $ 31,048 $ 29,057

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Measurements [Abstract]
Fair Value Measurements	Note H - Fair Value Measurements We measure our contingent purchase price considerations at fair value. The fair values of our contingent purchase price considerations, $9.2 million, are based on significant inputs not observable in the market, which require them to be reported as Level 3 liabilities within the fair value hierarchy. The valuation of these liabilities use assumptions we believe would be made by a market participant and are mainly based on estimates from a Monte Carlo simulation of our market capitalization and share price, as well as other factors impacting the probability of triggering the milestone payments. Market capitalization and share price were evolved using a geometric Brownian motion, calculated daily for the life of the contingent purchase price considerations. The significant unobservable inputs include the anticipated timelines to achieve the contingent purchase milestones and our estimated credit spread, the weighted average values of which (weighted based on the value of each contingent liability), are shown in the table below. March 31, 2021 December 31, 2020 Period of time to achieve milestones (in years) 1.2 1.3 Credit spread 4.7 % 5.5 % Liabilities measured at fair value are summarized below (in thousands): Description March 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price considerations $ 9,164 $ — $ — $ 9,164 Total $ 9,164 $ — $ — $ 9,164 Description December 31, 2020 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price consideration $ 10,208 $ — $ — $ 10,208 Total $ 10,208 $ — $ — $ 10,208 The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3), as of March 31, 2021 (in thousands): Balance, December 31, 2020 $ 10,208 Change in fair value of contingent purchase price considerations during the period (1,044 ) Balance, March 31, 2021 $ 9,164 The fair value of our outstanding debt balance at March 31, 2021 and December 31, 2020 was $20.5 million and $19.9 million, respectively, based on the Level 2 valuation hierarchy of the fair value measurements standard using a present value methodology that was derived by evaluating the nature and terms of each note and considering the prevailing economic and market conditions at the balance sheet date. The principal amount of our outstanding debt balance at March 31, 2021 and December 31, 2020 was $20.7 and $20.0 million, respectively.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2021
Collaboration [Abstract]
Revenue from Contracts with Customers	Note I - Revenue from Contracts with Customers Gilead Collaboration Agreement On December 20, 2018, we entered into a series of agreements with Gilead Sciences, Inc. (“Gilead”) focused on the development and commercialization of up to five novel immuno-oncology therapies. Pursuant to the terms of the license agreement, the option and license agreements and the stock purchase agreement we entered into with Gilead (collectively, the “Gilead Collaboration Agreements”), at the closing of the transaction on January 23, 2019, we received an upfront cash payment from Gilead of $120.0 million and Gilead made a $30.0 million equity investment in Agenus. On November 6, 2020, we received notice from Gilead that it was returning GS-1423 to us and voluntarily terminating the applicable license agreement. The termination was effective as of February 4, 2021. The option and license agreements and the stock purchase agreement remain in full force and effect. We remain eligible to receive up to $1.1 billion in aggregate potential milestones. Collaboration Revenue For the three months ended March 31, 2021, we recognized $1.0 million of research and development revenue related to the Gilead Collaboration Agreements based on the partial satisfaction of the over time performance obligations as of quarter end. For the three months ended March 31, 2020, we recognized $1.8 million of research and development revenue based on the partial satisfaction of the over time performance obligations as of quarter end. We expect to recognize deferred research and development revenue of $22.7 million and $20.4 million for the remainder of 2021 and 2022, respectively, related to performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2021. Incyte Collaboration Agreement For the three months ended March 31, 2021, we recognized approximately $0.5 million of research and development revenue for research and development services provided. For the three months ended March 31, 2020, we recognized approximately $0.1 million of research and development revenue for research and development services. Disaggregation of Revenue The following tables present revenue (in thousands) for the three months ended March 31, 2021 and 2020, disaggregated by geographic region and revenue type. Revenue by geographic region is allocated based on the domicile of our respective business operations. Three months ended March 31, 2021 United States Rest of World Total Revenue Type Research and development services $ 536 $ — $ 536 Other services — 1,629 1,629 Recognition of deferred revenue 1,035 — 1,035 Recognition of deferred grant revenue 35 — 35 Non-cash royalty revenue 8,484 — 8,484 $ 10,090 $ 1,629 $ 11,719 Three months ended March 31, 2020 Revenue Type Research and development services $ 97 $ — $ 97 Recognition of deferred revenue 1,831 — 1,831 Recognition of deferred grant revenue — 44 44 Non-cash royalty revenue 13,156 — 13,156 $ 15,084 $ 44 $ 15,128 Contract Balances Contract assets primarily relate to our rights to consideration for work completed in relation to our research and development services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, we do not have any contract assets which have not transferred to a receivable. The following table provides information about contract assets and contract liabilities from contracts with customers (in thousands): Three months ended March 31, 2021 Balance at beginning of period Additions Deductions Balance at end of period Contract assets: Unbilled receivables from collaboration partners $ - $ - $ - $ - Contract liabilities: Deferred revenue $ 45,284 $ - $ (1,053 ) $ 44,231 The change in contract liabilities is primarily related to the recognition of $1.0 million of revenue related to the Gilead Collaboration Agreements during the three months ended March 31, 2021. Deferred revenue related to the Gilead Collaboration Agreements of $43.1 million as of March 31, 2021, which was comprised of the $142.5 million initial transaction price, less $99.4 million of license and collaboration revenue recognized from the effective date of the contract, will be recognized as the combined performance obligation is satisfied. We also recorded a $2.2 million receivable as of March 31, 2021, for research and development and other services provided. During the three months ended March 31, 2021, we did not recognize any revenue from amounts included in the contract asset or the contract liability balances from performance obligations satisfied in previous periods. None of the costs to obtain or fulfill a contract were capitalized.

Share-Based Compensation Plans

Share-Based Compensation Plans	3 Months Ended
	Mar. 31, 2021
Share Based Compensation [Abstract]
Share-Based Compensation Plans	Note J - Share-based Compensation Plans We primarily use the Black-Scholes option pricing model to value stock options granted to employees and non-employees, including stock options granted to members of our Board of Directors. However, the fair value of stock option market-based awards is calculated based on a Monte Carlo simulation as of the date of issuance. All stock options have 10-year terms and generally vest ratably over a 3 or 4-year period. A summary of option activity for the three months ended March 31, 2021 is presented below: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2020 28,966,901 $ 3.70 Granted 2,475,436 3.67 Exercised (691,603 ) 3.24 Forfeited (475,344 ) 3.10 Expired (315,443 ) 4.53 Outstanding at March 31, 2021 29,959,947 $ 3.70 7.46 $ 3,093,793 Vested or expected to vest at March 31, 2021 29,959,947 $ 3.70 7.46 $ 3,093,793 Exercisable at March 31, 2021 15,021,351 $ 3.98 6.08 $ 1,350,486 The weighted average grant-date fair values of stock options granted during the three months ended March 31, 2021 and 2020 were $1.49 and $1.39, respectively. As of March 31, 2021, there was approximately $25.6 million of total unrecognized share-based compensation expense related to these stock options and stock options granted under a subsidiary plan which, if all milestones are achieved, will be recognized over a weighted average period of 2.3 years. Certain employees and consultants have been granted non-vested stock. The fair value of non-vested market-based awards is calculated based on a Monte Carlo simulation as of the date of issuance. The fair value of other non-vested stock is calculated based on the closing sale price of our common stock on the date of issuance. A summary of non-vested stock activity for the three months ended March 31, 2021 is presented below: Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 886,816 $ 2.14 Granted 255,000 3.53 Vested — — Forfeited — — Outstanding at March 31, 2021 1,141,816 $ 2.45 As of March 31, 2021, there was approximately $1.5 million of unrecognized share-based compensation expense related to these non-vested shares which will be recognized over a period of 1.5 years. During the three months ended March 31, 2021, 104,372 shares were issued under the 2019 Employee Stock Purchase Plan and 691,603 shares were issued as a result of stock option exercises. The impact on our results of operations from share-based compensation for the three months ended March 31, 2021 and 2020, was as follows (in thousands): Three Months Ended March 31, 2021 2020 Research and development $ 868 $ 1,203 General and administrative 3,064 1,194 Total share-based compensation expense $ 3,932 $ 2,397

Restricted Cash

Restricted Cash	3 Months Ended
	Mar. 31, 2021
Cash And Cash Equivalents [Abstract]
Restricted Cash	Note K – Restricted Cash As of March 31, 2021, and December 31, 2020, we maintained non-current restricted cash of $2.7 million and $2.6 million, respectively. This amount is included within “Other long-term assets” in our condensed consolidated balance sheets, and as of March 31, 2021, is comprised of letters of credit required under two of our facility leases. The following table provides a reconciliation of cash, cash equivalents and restricted cash that sums to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Beginning of Period End of Period Beginning of Period End of Period Cash and cash equivalents $ 99,871 $ 119,366 $ 61,808 $ 92,284 Restricted cash 2,634 2,669 — — Cash, cash equivalents and restricted cash $ 102,505 $ 122,035 $ 61,808 $ 92,284

Equity

Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Equity	Note L – Equity At the Market Offerings During the three months ended March 31, 2021, we received net proceeds of approximately $60.9 million from the sale of approximately 18.9 million shares of our common stock at an average price per share of approximately $3.31, in at-the-market offerings under our At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc. (“B. Riley”) dated July 22, 2020. Series C-1 Preferred Stock Conversion During the three months ended March 31, 2021, holders of shares of Series C-1 Preferred Stock converted a portion of such shares into 2.0 million shares of our common stock. As of March 31, 2021, 10,459 shares of Series C-1 Convertible Preferred Stock remained outstanding.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2021
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	Note M - Recent Accounting Pronouncements Recently Issued and Adopted In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 enhances and simplifies multiple aspects of the income tax accounting guidance in ASC 740. Recently Issued, Not Yet Adopted In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) that will eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, an impairment charge will be based on the excess of a reporting unit’s carrying amount over its fair value. The guidance is effective for the Company in the first quarter of fiscal 2023. Early adoption is permitted. We do not anticipate the adoption of this guidance to have a material impact on our consolidated financial statements, absent any goodwill impairment. No other new accounting pronouncement issued or effective during the three months ended March 31, 2021 had or is expected to have a material impact on our consolidated financial statements or disclosures.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note M – Subsequent Events At the Market Offerings During the period of April 1, 2021 through May 4, 2021, we received net proceeds of approximately $9.1 million from the sale of approximately 3.4 million shares of our common stock under the Sales Agreement.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following securities Three Months Ended March 31, 2021 2020 Warrants 1,950 2,025 Stock options 29,960 27,707 Non-vested shares 1,142 888 Series A-1 convertible preferred stock 333 333 Series C-1 convertible preferred stock 10,459 12,459

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2021
Cash And Cash Equivalents [Abstract]
Schedule of Cash Equivalents	Cash equivalents consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Cost Estimated Fair Value Cost Estimated Fair Value Institutional money market funds $ 94,928 $ 94,928 $ 64,256 $ 64,256 U.S. Treasury Bills 10,003 10,003 20,000 20,000 Total $ 104,931 $ 104,931 $ 84,256 $ 84,256

Goodwill and Acquired Intangi_2

Goodwill and Acquired Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes in Goodwill	The following table sets forth the changes in the carrying amount of goodwill for the three months ended March 31, 2021 (in thousands): Balance, December 31, 2020 $ 25,452 Foreign currency translation adjustment (1,118 ) Balance, March 31, 2021 $ 24,334
Schedule of Acquired Intangible Assets	Acquired intangible assets consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): As of March 31, 2021 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 16,698 $ (10,438 ) $ 6,260 Trademarks 4-4.5 years 1,245 (945 ) 300 Other 2-7 years 2,232 (793 ) 1,439 In-process research and development Indefinite 1,995 — 1,995 Total $ 22,170 $ (12,176 ) $ 9,994 As of December 31, 2020 Amortization period (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual property 7-15 years $ 17,013 $ (10,112 ) $ 6,901 Trademarks 4-4.5 years 1,310 (980 ) 330 Other 2-6 years 2,272 (749 ) 1,523 In-process research and development Indefinite 2,132 — 2,132 Total $ 22,727 $ (11,841 ) $ 10,886

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt Obligations	Debt obligations consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): Debt instrument Balance at March 31, 2021 Current Portion: Debentures $ 146 Other 1,317 Long-term Portion: 2015 Subordinated Notes 12,716 Other 6,197 Total $ 20,376 Debt instrument Balance at December 31, 2020 Current Portion: Debentures $ 146 Other 687 Long-term Portion: 2015 Subordinated Notes 12,682 Other 6,197 Total $ 19,712

Liability Related to the Sale_2

Liability Related to the Sale of Future Royalties and Milestones (Tables)	3 Months Ended
	Mar. 31, 2021
Text Block [Abstract]
Schedule of Liability Account	The following table shows the activity within the liability account in the three months ended March 31, 2021 (in thousands): Period from December 31, 2020 to March 31, 2021 Liability related to sale of future royalties and milestones - beginning balance $ 234,041 Non-cash royalty revenue (8,484 ) Non-cash interest expense recognized 15,562 Liability related to sale of future royalties and milestones - ending balance 241,119 Less: unamortized transaction costs (401 ) Liability related to sale of future royalties and milestones, net $ 240,718

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Other Liabilities Disclosure [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Payroll $ 10,966 $ 7,643 Professional fees 5,205 4,457 Contract manufacturing costs 5,669 6,274 Research services 4,348 4,649 Other 4,860 6,034 Total $ 31,048 $ 29,057

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Weighted Average Values of Contingent Purchase Milestones and Credit Spread	The significant unobservable inputs include the anticipated timelines to achieve the contingent purchase milestones and our estimated credit spread, the weighted average values of which (weighted based on the value of each contingent liability), are shown in the table below. March 31, 2021 December 31, 2020 Period of time to achieve milestones (in years) 1.2 1.3 Credit spread 4.7 % 5.5 %
Schedule of Liabilities Measured at Fair Value	Liabilities measured at fair value are summarized below (in thousands): Description March 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price considerations $ 9,164 $ — $ — $ 9,164 Total $ 9,164 $ — $ — $ 9,164 Description December 31, 2020 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Contingent purchase price consideration $ 10,208 $ — $ — $ 10,208 Total $ 10,208 $ — $ — $ 10,208
Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs	The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3), as of March 31, 2021 (in thousands): Balance, December 31, 2020 $ 10,208 Change in fair value of contingent purchase price considerations during the period (1,044 ) Balance, March 31, 2021 $ 9,164

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2021
Collaboration [Abstract]
Summary of Disaggregation of Revenue	The following tables present revenue (in thousands) for the three months ended March 31, 2021 and 2020, disaggregated by geographic region and revenue type. Revenue by geographic region is allocated based on the domicile of our respective business operations. Three months ended March 31, 2021 United States Rest of World Total Revenue Type Research and development services $ 536 $ — $ 536 Other services — 1,629 1,629 Recognition of deferred revenue 1,035 — 1,035 Recognition of deferred grant revenue 35 — 35 Non-cash royalty revenue 8,484 — 8,484 $ 10,090 $ 1,629 $ 11,719 Three months ended March 31, 2020 Revenue Type Research and development services $ 97 $ — $ 97 Recognition of deferred revenue 1,831 — 1,831 Recognition of deferred grant revenue — 44 44 Non-cash royalty revenue 13,156 — 13,156 $ 15,084 $ 44 $ 15,128
Schedule of Information about Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about contract assets and contract liabilities from contracts with customers (in thousands): Three months ended March 31, 2021 Balance at beginning of period Additions Deductions Balance at end of period Contract assets: Unbilled receivables from collaboration partners $ - $ - $ - $ - Contract liabilities: Deferred revenue $ 45,284 $ - $ (1,053 ) $ 44,231

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	3 Months Ended
	Mar. 31, 2021
Share Based Compensation [Abstract]
Schedule of Stock Option Activity	A summary of option activity for the three months ended March 31, 2021 is presented below: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at December 31, 2020 28,966,901 $ 3.70 Granted 2,475,436 3.67 Exercised (691,603 ) 3.24 Forfeited (475,344 ) 3.10 Expired (315,443 ) 4.53 Outstanding at March 31, 2021 29,959,947 $ 3.70 7.46 $ 3,093,793 Vested or expected to vest at March 31, 2021 29,959,947 $ 3.70 7.46 $ 3,093,793 Exercisable at March 31, 2021 15,021,351 $ 3.98 6.08 $ 1,350,486
Summary of Non-vested Stock Activity	A summary of non-vested stock activity for the three months ended March 31, 2021 is presented below: Non-vested Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2020 886,816 $ 2.14 Granted 255,000 3.53 Vested — — Forfeited — — Outstanding at March 31, 2021 1,141,816 $ 2.45
Schedule of Share-Based Compensation Expense	The impact on our results of operations from share-based compensation for the three months ended March 31, 2021 and 2020, was as follows (in thousands): Three Months Ended March 31, 2021 2020 Research and development $ 868 $ 1,203 General and administrative 3,064 1,194 Total share-based compensation expense $ 3,932 $ 2,397

Restricted Cash (Tables)

Restricted Cash (Tables)	3 Months Ended
	Mar. 31, 2021
Cash And Cash Equivalents [Abstract]
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash that sums to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Beginning of Period End of Period Beginning of Period End of Period Cash and cash equivalents $ 99,871 $ 119,366 $ 61,808 $ 92,284 Restricted cash 2,634 2,669 — — Cash, cash equivalents and restricted cash $ 102,505 $ 122,035 $ 61,808 $ 92,284

Business, Liquidity and Basis_2

Business, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Description Of Business [Abstract]
Cash and cash equivalents	$ 119,366	$ 99,871	$ 92,284	$ 61,808
Increase in cash and cash equivalents	19,500
Accumulated deficit	$ 1,519,584	$ 1,465,907

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding) (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,950	2,025
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	29,960	27,707
Non-vested Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,142	888
Series A-1 convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	333	333
Series C-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,459	12,459

Investments (Schedule of Cash E

Investments (Schedule of Cash Equivalents) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Cost [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	$ 104,931	$ 84,256
Estimated Fair Value [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	104,931	84,256
Institutional Money Market Funds [Member] | Cost [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	94,928	64,256
Institutional Money Market Funds [Member] | Estimated Fair Value [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	94,928	64,256
U.S. Treasury Bills [Member] | Cost [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	10,003	20,000
U.S. Treasury Bills [Member] | Estimated Fair Value [Member]
Cash And Cash Equivalents [Line Items]
Cash equivalents	$ 10,003	$ 20,000

Goodwill and Acquired Intangi_3

Goodwill and Acquired Intangible Assets (Schedule of Changes in Goodwill) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 25,452
Foreign currency translation adjustment	(1,118)
Ending balance	$ 24,334

Goodwill and Acquired Intangi_4

Goodwill and Acquired Intangible Assets (Acquired Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross (Excluding Goodwill)	$ 22,170	$ 22,727
Accumulated amortization	(12,176)	(11,841)
Net carrying amount	9,994	10,886
Indefinite-lived Intangible Assets Acquired	1,995	2,132
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	16,698	17,013
Accumulated amortization	(10,438)	(10,112)
Net carrying amount	$ 6,260	$ 6,901
Intellectual Property [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	7 years	7 years
Intellectual Property [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	15 years	15 years
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,245	$ 1,310
Accumulated amortization	(945)	(980)
Net carrying amount	$ 300	$ 330
Trademarks [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	4 years	4 years
Trademarks [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	4 years 6 months	4 years 6 months
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,232	$ 2,272
Accumulated amortization	(793)	(749)
Net carrying amount	$ 1,439	$ 1,523
Other [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	2 years	2 years
Other [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	7 years	6 years

Goodwill and Acquired Intangi_5

Goodwill and Acquired Intangible Assets (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2021	$ 1.6
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2022	2.2
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2023	1.7
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2024	0.6
Finite-Lived Intangible Assets, Estimated Amortization Expense, December 31, 2025	$ 0.6

Debt - Schedule of Debt Obligat

Debt - Schedule of Debt Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Other	$ 1,317	$ 687
Total	20,376	19,712
2015 Subordinated Notes [Member]
Debt Instrument [Line Items]
2015 Subordinated Notes	12,716	12,682
Other services [Member]
Debt Instrument [Line Items]
Other	6,197	6,197
Debentures [Member]
Debt Instrument [Line Items]
Debentures	$ 146	$ 146

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended
	May 31, 2020	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal amount of outstanding debt		$ 20.7	$ 20
Paycheck Protection Program [Member] | COVID 19 [Member]
Debt Instrument [Line Items]
Loan term	2 years
Percentage of loan proceeds to be used for payroll costs	60.00%
Percentage of loan proceeds to be used for rent and utilities	40.00%
Debt instrument, interest rate, stated percentage	1.00%
Paycheck Protection Program [Member] | Promissory notes with Bank of America [Member] | COVID 19 [Member]
Debt Instrument [Line Items]
Aggregate loan proceeds	$ 6.2

Liability Related to the Sale_3

Liability Related to the Sale of Future Royalties and Milestones (Schedule of Liability Account) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Liability Related To Sale Of Future Royalties And Milestones [Abstract]
Liability related to sale of future royalties and milestones - beginning balance	$ 234,041
Non-cash royalty revenue	(8,484)
Non-cash interest expense recognized	15,562
Liability related to sale of future royalties and milestones - ending balance	241,119
Less: unamortized transaction costs	(401)
Liability related to sale of future royalties and milestones, net	$ 240,718

Liability Related to the Sale_4

Liability Related to the Sale of Future Royalties and Milestones (Narrative) (Details) - USD ($) $ in Thousands	Jan. 19, 2018	Mar. 31, 2021	Jan. 06, 2018
Liability Related To Sale Of Future Royalties And Milestones [Line Items]
Non-cash royalty revenue recognized		$ 8,484
Non-cash interest expense		15,562
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member]
Liability Related To Sale Of Future Royalties And Milestones [Line Items]
Percentage of purchase of worldwide rights to receive royalties			100.00%
Gross proceeds received for royalty rights	$ 190,000
Non-cash royalty revenue recognized		8,500
Non-cash interest expense		$ 15,600
Effective annual interest rate		28.30%
Prospective effective annual interest rate		23.60%

Accrued Liabilities (Schedule o

Accrued Liabilities (Schedule of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Payroll	$ 10,966	$ 7,643
Professional fees	5,205	4,457
Contract manufacturing costs	5,669	6,274
Research services	4,348	4,649
Other	4,860	6,034
Total	$ 31,048	$ 29,057

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price considerations	$ 9,164	$ 10,208
Long-term Debt, Gross	20,700	20,000
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent purchase price considerations	0	0
Debt Instrument, Fair Value Disclosure	$ 20,500	$ 19,900

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Weighted Average Values of Contingent Purchase Milestones and Credit Spread) (Details) - Weighted Average [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Period of time to achieve milestones (in years)	1 year 2 months 12 days	1 year 3 months 18 days
Credit spread	4.70%	5.50%

Fair Value Measurements (Sche_2

Fair Value Measurements (Schedule of Liabilities Measured at Fair Value) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	$ 9,164	$ 10,208
Total	9,164	10,208
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	0	0
Total	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	0	0
Total	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent purchase price considerations, Fair Value Disclosure	9,164	10,208
Total	$ 9,164	$ 10,208

Fair Value Measurements (Sche_3

Fair Value Measurements (Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs) (Details) - Significant Unobservable Inputs (Level 3) [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Balance, beginning of period	$ 10,208
Balance, end of period	9,164
Contingent Purchase Price [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Change in fair value of considerations during the period	$ (1,044)

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Narrative) (Details) - USD ($)	Jan. 23, 2019	Mar. 31, 2021	Mar. 31, 2020
Revenue From Contract With Customer [Line Items]
Shares sold at the market		$ 60,859,000	$ 65,123,000
Revenue recognized		11,719,000	15,128,000
Asset impairment charges		0
Contract with customer, liability, revenue recognized		1,053,000
Capitalized contract , cost		0
Research and Development Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue recognized		1,571,000	1,928,000
Research and Development Services [Member]
Revenue From Contract With Customer [Line Items]
Revenue recognized		536,000	97,000
Gilead Collaboration Arrangements [Member]
Revenue From Contract With Customer [Line Items]
Contract with customer, liability, revenue recognized		1,000,000
Contract with customer, net asset liability		43,100,000
Initial transaction price		142,500,000
Gilead Collaboration Arrangements [Member] | License and Collaboration Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue recognized		99,400,000
Gilead Sciences Incorporation [Member] | Gilead Collaboration Arrangements [Member]
Revenue From Contract With Customer [Line Items]
Upfront cash payment	$ 120,000,000
Shares sold at the market	30,000,000
Gilead Sciences Incorporation [Member] | Gilead Collaboration Arrangements [Member] | Research and Development Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue recognized		1,000,000	1,800,000
Incyte Corporation [Member]
Revenue From Contract With Customer [Line Items]
Receivables for R & D services		2,200,000
Incyte Corporation [Member] | Incyte Collaboration Agreement [Member] | Research and Development Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue recognized			$ 100,000
Incyte Corporation [Member] | Incyte Collaboration Agreement [Member] | Research and Development Services [Member]
Revenue From Contract With Customer [Line Items]
Revenue recognized		$ 500,000
Maximum [Member] | Gilead Sciences Incorporation [Member] | Gilead Collaboration Arrangements [Member]
Revenue From Contract With Customer [Line Items]
Aggregate potential milestones receivable	$ 1,100,000,000

Revenue from Contracts with C_4

Revenue from Contracts with Customers (Narrative) (Details 1) - Gilead Sciences Incorporation [Member] $ in Millions	Mar. 31, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-04-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Expect to recognize deferred research and development revenue	$ 22.7
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Expect to recognize deferred research and development revenue	$ 20.4
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue from Contracts with C_5

Revenue from Contracts with Customers (Summary of Disaggregation of Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 11,719	$ 15,128
Research and development services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	536	97
Other services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,629
Recognition of deferred revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,035	1,831
Non-cash royalty revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	8,484	13,156
Recognition of deferred grant revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	35	44
Non-cash royalty revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue		13,156
United States [Member]
Disaggregation Of Revenue [Line Items]
Revenue	10,090	15,084
United States [Member] | Research and development services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	536	97
United States [Member] | Recognition of deferred revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,035	1,831
United States [Member] | Non-cash royalty revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	8,484
United States [Member] | Recognition of deferred grant revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue	35
United States [Member] | Non-cash royalty revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue		13,156
Rest of World [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,629	44
Rest of World [Member] | Other services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,629
Rest of World [Member] | Recognition of deferred grant revenue [Member]
Disaggregation Of Revenue [Line Items]
Revenue		$ 44

Revenue from Contracts with C_6

Revenue from Contracts with Customers (Schedule of Information about Contract Assets and Contract Liabilities from Contracts with Customers) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Contract With Customer Asset And Liability [Abstract]
Deferred revenue, Beginning Balance	$ 45,284
Deferred revenue, Deductions	(1,053)
Deferred revenue, Ending Balance	$ 44,231

Share-Based Compensation Plan_2

Share-Based Compensation Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average grant-date fair value of options granted	$ 1.49	$ 1.39
Shares issued from exercise of options	691,603
Employees and directors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized share-based compensation expense	$ 25.6
Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized share-based compensation expense, weighted average period	2 years 3 months 18 days
Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized share-based compensation expense	$ 1.5
Performance Based Award [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized share-based compensation expense, weighted average period	1 year 6 months
2009 EIP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	10 years
2009 EIP [Member] | Minimum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period, minimum	3 years
2009 EIP [Member] | Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period, minimum	4 years
2019 ESPP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares issued under ESPP	104,372

Share-Based Compensation Plan_3

Share-Based Compensation Plans (Schedule of Stock Option Activity) (Details)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Share Based Compensation [Abstract]
Options Outstanding, Beginning Balance | shares	28,966,901
Options Granted | shares	2,475,436
Options Exercised | shares	(691,603)
Options Forfeited | shares	(475,344)
Options Expired | shares	(315,443)
Options Outstanding, Ending Balance | shares	29,959,947
Options Vested or expected to vest | shares	29,959,947
Options Exercisable | shares	15,021,351
Options Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 3.70
Options Granted, Weighted Average Exercise Price | $ / shares	3.67
Options Exercised, Weighted Average Exercise Price | $ / shares	3.24
Options Forfeited, Weighted Average Exercise Price | $ / shares	3.10
Options Expired, Weighted Average Exercise Price | $ / shares	4.53
Options Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares	3.70
Options Vested or expected to vest, Weighted Average Exercise Price | $ / shares	3.70
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 3.98
Options Outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 15 days
Options Vested or expected to vest, Weighted Average Remaining Contractual Term	7 years 5 months 15 days
Options Exercisable, Weighted Average Remaining Contractual Term	6 years 29 days
Options Outstanding, Aggregate Intrinsic Value | $	$ 3,093,793
Options Vested or expected to vest, Aggregate Intrinsic Value | $	3,093,793
Options Exercisable, Aggregate Intrinsic Value | $	$ 1,350,486

Share-Based Compensation Plan_4

Share-Based Compensation Plans (Summary of Non-vested Stock Activity) (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share Based Compensation [Abstract]
Non-vested Shares Outstanding, Beginning Balance | shares	886,816
Non-vested Shares Granted | shares	255,000
Non-vested Shares Outstanding, Ending Balance | shares	1,141,816
Non-vested Shares Outstanding, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.14
Non-vested Shares Granted, Weighted Average Grant Date Fair Value | $ / shares	3.53
Non-vested Shares Outstanding, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.45

Share-Based Compensation Plan_5

Share-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 3,932	$ 2,397
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	868	1,203
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 3,064	$ 1,194

Restricted Cash (Narrative) (De

Restricted Cash (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Cash And Cash Equivalents [Abstract]
Restricted cash	$ 2,669	$ 2,634

Restricted Cash (Schedule of Re

Restricted Cash (Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents	$ 119,366	$ 99,871	$ 92,284	$ 61,808
Restricted cash	2,669	2,634
Cash, cash equivalents and restricted cash	$ 122,035	$ 102,505	$ 92,284	$ 61,808

Equity (Narrative) (Details)

Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Series C-1 Convertible Preferred Stock [Member]
Class Of Stock [Line Items]
Conversion of preferred stock into common stock	2,000,000
Series C-1 convertible preferred stock, shares outstanding	10,459	12,459	12,000	12,000
At Market Issuance Sales Agreement [Member] | B. Riley FBR, Inc. [Member] | New Sales Agreement [Member]
Class Of Stock [Line Items]
Net proceeds from issuance of common stock	$ 60.9
Shares sold at the market, shares	18,900,000
Shares sold price per share	$ 3.31

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - At Market Issuance Sales Agreement [Member] - B. Riley FBR, Inc. [Member] - New Sales Agreement [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	May 04, 2021	Mar. 31, 2021
Subsequent Event [Line Items]
Net proceeds from issuance of common stock		$ 60.9
Shares sold at the market, shares		18,900,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Net proceeds from issuance of common stock	$ 9.1
Shares sold at the market, shares	3,400,000